A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: Validation with daunomycin, doxorubicin, and the alpha particle emitter 210Po

Nuclear Medicine and Biology

Volumn 39, Issue 7, 2012, Pages 954-961

  Akudugu, John M ^a,b   Howell, Roger W ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Alpha particle; Chemotherapy; Drug cocktail; Monte Carlo; Radionuclide therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CITRATE PO 210; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANALYTIC METHOD; ANIMAL CELL; ARTICLE; CELL POPULATION; CELL SURVIVAL; CELL TRANSPORT; COLONY FORMING CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; FLOW CYTOMETRY; MONTE CARLO METHOD; NONHUMAN; RADIOCHEMISTRY; VALIDATION STUDY;

ALPHA PARTICLES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE; CELL SURVIVAL; CRICETINAE; DAUNORUBICIN; DOXORUBICIN; MONTE CARLO METHOD; POLONIUM; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 84866015067     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.01.011     Document Type: Article

References (45)

1. Sharkey R.M., Goldenberg D.M. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev 2008, 60:1407-1420.
2. Song H., Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv 2011, 8:26-44.
3. 111In-labeled antibodies to HER-2. Mol Cancer Ther 2005, 4:927-937.
4. Hou D.Y., Hoch H., Johnston G.S., Tsou K.C., Jones A.E., Farkas R.J., et al. A new In-111 bleomycin complex for combined radiotherapy and chemotherapy. J Surg Oncol 1985, 29:91-98.
5. Howell R.W., Sastry K.S.R., Hill H.Z., Rao D.V. Cis-platinum-193m: its microdosimetry and potential for chemo-Auger combination therapy of cancer. Proceedings of Fourth International Radiopharmaceutical Dosimetry Symposium 1986, 493-513. National Technical Information Service, Springfield (Va). A.T. Schlafke-Stelson, E.E. Watson (Eds.).
6. Azure M.T., Sastry K.S.R., Archer R.D., Howell R.W., Rao D.V. Microscale synthesis of carboplatin labeled with the Auger emitter Pt-193m: radiotoxicity versus chemotoxicity of the antitumor drug in mammalian cells. Biophysical aspects of Auger processes 1992, 336-351. American Institute of Physics, Woodbury, NY. http://www.aapm.org/pubs/books/default.asp, R.W. Howell, V.R. Narra, K.S.R. Sastry, D.V. Rao (Eds.).
7. 195mPt labeled trans-platinum(II) in mammalian cells. Radiat Res 1994, 140:55-62.
8. 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy. Nucl Med Biol 2006, 33:773-783.
9. DeNardo S.J., Kukis D.L., Kroger L.A., O'Donnell R.T., Lamborn K.R., Miers L.A., et al. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA 1997, 94:4000-4004.
10. 111In-NLS-Trastuzumab. J Nucl Med 2010, 51:477-483.
11. Jurcic J.G., Larson S.M., Sgouros G., McDevitt M.R., Finn R.D., Divgi C.R., et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002, 100:1233-1239.
12. Juweid M., Sharkey R.M., Markowitz A., Behr T., Swayne L.C., Dunn R., et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995, 55:5899s-5907s.
13. Vriesendorp H.M., Herpst J.M., Germack M.A., Klein J.L., Leichner P.K., Loudenslager D.M., et al. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol 1991, 9:918-928.
14. Wiseman G.A., White C.A., Stabin M., Dunn W.L., Erwin W., Dahlbom M., et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000, 27:766-777.
15. Meredith R.F., Bueschen A.J., Khazaeli M.B., Plott W.E., Grizzle W.E., Wheeler R.H., et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994, 35:1017-1022.
16. Juweid M.E., Sharkey R.M., Behr T., Swayne L.C., Dunn R., Siegel J., et al. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2. J Nucl Med 1996, 37:1504-1510.
17. Behr T.M., Liersch T., Greiner-Bechert L., Griesinger F., Behe M., Markus P.M., et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002, 94:1373-1381.
18. Breitz H.B., Weiden P.L., Vanderheyden J.L., Applebaum J.W., Bjorn M.J., Fer M.F., et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J Nucl Med 1992, 33:1099-1112.
19. Boerman O.C., Koppe M.J., Postema E.J., Corstens F.H., Oyen W.J. Radionuclide therapy of cancer with radiolabeled antibodies. Anticancer Agents Med Chem 2007, 7:335-343.
20. Wessels B.W., Rogus R.D. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984, 11:638-645.
21. Humm J.L. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986, 27:1490-1497.
22. Howell R.W., Rao D.V., Sastry K.S.R. Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors. Med Phys 1989, 16:66-74.
23. Kvinnsland Y., Stokke T., Aurlien E. Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiat Res 2001, 155:288-296.
24. Akudugu J.M., Neti P.V.S.V., Howell R.W. Changes in lognormal shape parameter guide design of patient-specific radiochemotherapy cocktails. J Nucl Med 2011, 52:642-649.
25. Neti P.V., Howell R.W. Log normal distribution of cellular uptake of radioactivity: implications for biologic responses to radiopharmaceuticals. J Nucl Med 2006, 47:1049-1058.
26. Goddu S.M., Rao D.V., Howell R.W. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med 1994, 35:521-530.
27. O'Donoghue J.A. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med 1999, 40:1337-1341.
28. Singh Jaggi J., Henke E., Seshan S.V., Kappel B.J., Chattopadhyay D., May C., et al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One 2007, 2:e267.
29. Sgouros G., Roeske J.C., McDevitt M.R., Palm S., Allen B.J., Fisher D.R., et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 2010, 51:311-328.
30. 89Sr in mice. J Nucl Med 2003, 44:252-259.
31. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an α-emitter in vivo. J Nucl Med 2005, 46:2061-2067.
32. Mulford D.A., Scheinberg D.A., Jurcic J.G. The promise of targeted {alpha}-particle therapy. J Nucl Med 2005, 46(Suppl 1):199S-204S.
33. Lucignani G. Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213. Eur J Nucl Med Mol Imaging 2008, 35:1729-1733.
34. DeNardo S.J., Denardo G.L. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys 2006, 66:S89-95.
35. 213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res 2007, 67:1950-1958.
36. Neti P.V., Howell R.W. Lognormal distribution of cellular uptake of radioactivity: statistical analysis of alpha-particle track autoradiography. J Nucl Med 2008, 49:1009-1016.
37. Akudugu J.M., Howell R.W. Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs. Int J Radiat Biol 2012, 88:286-293.
38. Gerlinger M., Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010, 103:1139-1143.
39. Saylor C., Dadachova E., Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009, 27(Suppl 6):G38-46.
40. Tsang C.N., Ho K.S., Sun H., Chan W.T. Tracking bismuth antiulcer drug uptake in single Helicobacter pylori cells. J Am Chem Soc 2011, 133:7355-7357.
41. Bishayee A., Rao D.V., Howell R.W. Evidence for pronounced bystander effects caused by nonuniform distributions of radioactivity using a novel three-dimensional tissue culture model. Radiat Res 1999, 152:88-97.
42. Eckerman K.F., Endo A. MIRD: radionuclide data and decay schemes 2008, Society of Nuclear Medicine, Reston, VA. 2nd ed.
43. Rajon D., Bolch W.E., Howell R.W. Lognormal distribution of cellular uptake of radioactivity: Monte Carlo simulation of irradiation and cell killing in 3-dimensional populations in carbon scaffolds. J Nucl Med 2011, 52:926-933.
44. Akudugu J.M., Slabbert J.P., Roos W.P., Bohm L. Micronucleus response of human glioblastoma and neuroblastoma cells toward low-LET photon and high-LET p(66)/Be neutron irradiation. Am J Clin Oncol 2003, 26:e1-6.
45. Sharkey R.M., Rossi E.A., Chang C.H., Goldenberg D.M. Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies. Cancer Biother Radiopharm 2010, 25:1-12.